Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Gains from Sales and Divestitures (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $154077.0 as the latest value for Q1 2026.

  • For Q1 2026, Gains from Sales and Divestitures fell 69.7% year-over-year to $154077.0; the TTM value through Mar 2026 reached $154077.0, down 69.7%, while the annual FY2025 figure was $1.5 million, 53.5% up from the prior year.
  • Gains from Sales and Divestitures hit $154077.0 in Q1 2026 for Phathom Pharmaceuticals, down from $1.5 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.5 million in Q4 2025 and bottomed at $102453.0 in Q4 2022.
  • Average Gains from Sales and Divestitures over 5 years is $631010.2, with a median of $428558.0 recorded in 2023.
  • Year-over-year, Gains from Sales and Divestitures skyrocketed 885.77% in 2023 and then plummeted 69.7% in 2026.
  • Phathom Pharmaceuticals' Gains from Sales and Divestitures stood at $102453.0 in 2022, then surged by 885.77% to $1.0 million in 2023, then dropped by 4.36% to $965881.0 in 2024, then skyrocketed by 53.5% to $1.5 million in 2025, then plummeted by 89.61% to $154077.0 in 2026.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $154077.0, $1.5 million, and $1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.